Immunologic Factor – Page 30

Kinevant Sciences Discontinues Namilumab Development for Pulmonary Sarcoidosis Following Phase 2 Failure

9 months ago talkbio0Tagged Anti-GM-CSF, Kinevant, Monoclonal Antibodies, namilumab, Phase 2 Clinical Trials, Sarcoidosis, Pulmonary, Science

Namilumab, Pulmonary Sarcoidosis, Phase 2 Study, Kinevant Sciences, RESOLVE-Lung Study, Anti-GM-CSF Monoclonal Antibody

Gilead Partners with Tubulis to Revitalize ADC Pipeline

9 months ago talkbio0Tagged Antibody-Drug, Antibody-Drug Conjugates, Biotechnology, Gilead Sciences, Immunostimulating conjugate (antigen), Malignant Neoplasms, Partnership, Tubulis

Gilead Sciences, Tubulis, Antibody-Drug Conjugates (ADCs), Cancer Treatment, Biotechnology Partnership

Takeda Acquires Rights to Rival BMS’ Reblozyl with $200M Upfront Payment to Keros

9 months ago talkbio0Tagged Bristol Myers Squibb, Dosage Forms, Malignant Neoplasms, Reblozyl, Takeda

Takeda, Keros Therapeutics, Bristol-Myers Squibb, Reblozyl, Cancer Treatment, Pharmaceutical Deal

Merus’s Petosemtamab Demonstrates Promising Efficacy in Expanded HNSCC Dataset

9 months ago talkbio0Tagged Clinical Trials, Congress (U.S. Legislature), ESMO, Head, Malignant Neoplasms, Merus, MRUS, N.V., Petosemtamab, Squamous cell carcinoma of the head and neck

Petosemtamab, HNSCC (Head and Neck Squamous Cell Carcinoma), Merus N.V. (MRUS), Clinical Trial Results, Cancer Treatment, ESMO Asia Congress 2024

Merus’ Petosemtamab Demonstrates Promising Efficacy in Head and Neck Cancer, Enhancing Its ‘Best-in-Disease’ Profile

10 months ago talkbio0Tagged Biclonics, Cancer of Neck, Clinical Trials, Congress (U.S. Legislature), Epidermal Growth Factor Receptor, ESMO, LGR5 gene, Merus, Petosemtamab

Petosemtamab, Head and Neck Cancer, Clinical Trials, Merus, ESMO Asia Congress 2024, Biclonics, EGFR and LGR5

Merck and Kelun-Biotech Advance in Cancer Treatment with Exclusive License Agreement for Investigational ADC Candidates

10 months ago talkbio0Tagged Antibody-Drug, Antibody-Drug Conjugates, Immunostimulating conjugate (antigen), Kelun-Biotech, Malignant Neoplasms, Merck, NECTIN4 gene, SKB571, TROP2

Merck, Kelun-Biotech, Antibody-Drug Conjugates (ADC), Cancer Treatment, Exclusive License Agreement, TROP2, Nectin-4, SKB571

European Commission Approves BeiGene’s TEVIMBRA for First-Line Treatment of Advanced/Metastatic Esophageal Squamous Cell Carcinoma and Gastric or Gastroesophageal Junction Cancer

10 months ago talkbio0Tagged BeiGene, Cancer Therapeutic Procedure, Commission approval, European (ethnic group), first-line, Gastroesophageal Junction Adenocarcinoma, Squamous cell carcinoma of esophagus, Stomach, Tevimbra, tislelizumab

TEVIMBRA, tislelizumab, European Commission approval, first-line treatment, esophageal squamous cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, cancer treatment, BeiGene.

Roche’s TIGIT Drug Candidate Tiragolumab Fails to Meet Overall Survival Endpoint in Phase 3 Lung Cancer Trial

10 months ago talkbio0Tagged Keytruda, Malignant neoplasm of lung, Overall Survival, Phase 3 trial, Roche (company), Skyscraper-01, Tecentriq, TIGIT gene, Tiragolumab

Roche, TIGIT, tiragolumab, lung cancer, phase 3 trial, SKYSCRAPER-01, overall survival, Keytruda, Tecentriq

Gilead Sciences Acquires Investigational HIV Vaccine Assets from AELIX Therapeutics

10 months ago talkbio0Tagged Antigens, Gilead Sciences, HIV Vaccine, HIVACAT, HTI

Gilead Sciences, AELIX Therapeutics, HIV vaccine, HTI immunogen, IrsiCaixa, HIVACAT program

Biopharma Industry Braces for Uncertainty Under Trump’s Second Term: Impact on Vaccines and M&A Deals

10 months ago talkbio0Tagged Biopharma Industry, Changing, FTC, Health Policy, M&A, Policy, Regulation, second, Trump 's, United States Federal Trade Commission, Vaccines

Trump’s second term, Biopharma industry, Vaccine regulation, Robert F. Kennedy Jr., M&A deals, FTC policy changes, Healthcare policy uncertainty